DK3722274T3 - 2-perfluorbutylpentan til oftalmisk indgivelse - Google Patents

2-perfluorbutylpentan til oftalmisk indgivelse Download PDF

Info

Publication number
DK3722274T3
DK3722274T3 DK20172665.0T DK20172665T DK3722274T3 DK 3722274 T3 DK3722274 T3 DK 3722274T3 DK 20172665 T DK20172665 T DK 20172665T DK 3722274 T3 DK3722274 T3 DK 3722274T3
Authority
DK
Denmark
Prior art keywords
perfluorbutylpentane
ophthalmic administration
ophthalmic
administration
Prior art date
Application number
DK20172665.0T
Other languages
Danish (da)
English (en)
Inventor
Frank LÖSCHER
Ralf Grillenberger
Dieter Scherer
Hartmut Voss
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Application granted granted Critical
Publication of DK3722274T3 publication Critical patent/DK3722274T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/266—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20172665.0T 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse DK3722274T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15187760 2015-09-30
EP15192429 2015-10-30
EP16775673.3A EP3356313B1 (en) 2015-09-30 2016-09-29 2-perfluorohexyl octane for ophthalmic administration

Publications (1)

Publication Number Publication Date
DK3722274T3 true DK3722274T3 (da) 2023-09-11

Family

ID=57068093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20172665.0T DK3722274T3 (da) 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse
DK16775673.3T DK3356313T3 (da) 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK16775673.3T DK3356313T3 (da) 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse

Country Status (14)

Country Link
US (2) US11154513B2 (enExample)
EP (3) EP3722274B1 (enExample)
JP (2) JP6642935B2 (enExample)
KR (2) KR102584063B1 (enExample)
CN (4) CN113662928A (enExample)
AU (3) AU2016329261B2 (enExample)
CA (1) CA2998269C (enExample)
DE (1) DE202016008739U1 (enExample)
DK (2) DK3722274T3 (enExample)
ES (2) ES2803248T3 (enExample)
MX (2) MX2018003781A (enExample)
PL (2) PL3356313T3 (enExample)
PT (1) PT3356313T (enExample)
WO (1) WO2017055453A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
AU2013314370B2 (en) 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
KR102584063B1 (ko) * 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
JP7032404B2 (ja) * 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物
JP7072582B2 (ja) 2017-04-21 2022-05-20 ノバリック ゲーエムベーハー ヨウ素組成物
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (zh) * 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
KR102808092B1 (ko) 2018-09-27 2025-05-22 더마리크 테라퓨틱스, 인크. 지질 장벽 수복
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
EP4025235A1 (en) 2019-09-06 2022-07-13 Novaliq GmbH Ophthalmic composition for the treatment of uveitis

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DE69907341T2 (de) 1998-02-09 2004-01-22 Macrochem Corp., Lexington Antimykotischer nagellack
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
EP1666026B2 (en) 1999-02-08 2015-02-25 Intarcia Therapeutics, Inc Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same
EP1124416A1 (en) 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
CA2459483C (en) 2001-09-04 2009-06-23 Trommsdorff Gmbh & Co. Kg Arzneimittel Plaster for the treatment of dysfunctions and disorders of nail growth
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
KR20060113657A (ko) 2003-08-25 2006-11-02 포믹스 리미티드 침투성 약제용 거품제
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
WO2005051305A2 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
ES2387619T3 (es) 2004-04-19 2012-09-27 Centre National De La Recherche Scientifique (Cnrs) Suplementos de tensioactivos pulmonares
WO2005123035A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
JP2008505177A (ja) 2004-07-01 2008-02-21 ザ・シェペンズ・アイ・リサーチ・インスティテュート・インコーポレーテッド 目の障害および状態を治療するための組成物および方法
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
CN101304728A (zh) 2005-08-05 2008-11-12 印度血清及疫苗有限公司 具有防腐功效的静脉内用丙泊酚乳剂组合物
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2008011836A2 (es) 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
AU2007281918A1 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
EP2099408B1 (en) 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR20090087917A (ko) 2006-12-07 2009-08-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
PL2110126T3 (pl) 2008-04-18 2012-04-30 Novaliq Gmbh Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
JP5739344B2 (ja) 2008-10-31 2015-06-24 ザ ユニヴァーシティー オブ ミシシッピ Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法
JP2012509737A (ja) 2008-11-26 2012-04-26 サーモディクス，インコーポレイティド 埋め込み式の眼薬送達器具および眼薬送達方法
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5549669B2 (ja) 2009-06-25 2014-07-16 ライオン株式会社 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
PL2387391T3 (pl) 2009-07-24 2017-09-29 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Sposób otrzymywania ciekłej kompozycji stosowalnej w postaci piany na skórę oraz kompozycja do aplikowania miejscowego
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
DE102010022567A1 (de) * 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
BR112013016661B1 (pt) 2011-01-04 2021-08-03 Novaliq Gmbh Emulsões de o/a compreendendo alcanos semifluorados
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
AU2013314370B2 (en) 2012-09-12 2017-11-30 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
WO2015053829A1 (en) 2013-10-09 2015-04-16 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
WO2015153469A1 (en) 2014-03-31 2015-10-08 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
US10123904B2 (en) 2014-08-13 2018-11-13 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
KR102584063B1 (ko) 2015-09-30 2023-09-27 노바리크 게엠베하 부분불소화 화합물
EP3495023B1 (en) * 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
CA3036306C (en) 2016-09-23 2024-05-14 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP3518921B1 (en) 2016-09-28 2021-08-11 Novaliq GmbH Compositions comprising a cannabinoid receptor binding ligand
CA3045733C (en) 2016-12-22 2024-01-16 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
JP7032404B2 (ja) 2016-12-23 2022-03-08 ノバリック ゲーエムベーハー ドライアイ疾患の治療のための眼科用組成物

Also Published As

Publication number Publication date
JP7050741B2 (ja) 2022-04-08
EP4234523A1 (en) 2023-08-30
CN108349855B (zh) 2021-07-20
US20170087101A1 (en) 2017-03-30
EP3356313A1 (en) 2018-08-08
AU2016329261A1 (en) 2018-04-12
ES2803248T3 (es) 2021-01-25
JP2020073551A (ja) 2020-05-14
PT3356313T (pt) 2020-07-13
AU2022200366B2 (en) 2023-11-09
CN113662929A (zh) 2021-11-19
EP3356313B1 (en) 2020-05-06
WO2017055453A1 (en) 2017-04-06
HK1257182A1 (en) 2019-10-18
PL3356313T3 (pl) 2020-11-16
ES2953837T3 (es) 2023-11-16
CA2998269A1 (en) 2017-04-06
US20210315832A1 (en) 2021-10-14
CN108349855A (zh) 2018-07-31
AU2020205239A1 (en) 2020-07-30
CA2998269C (en) 2021-03-23
AU2020205239B2 (en) 2021-10-21
JP6642935B2 (ja) 2020-02-12
MX391587B (es) 2025-03-21
KR20180059823A (ko) 2018-06-05
KR102584063B1 (ko) 2023-09-27
EP3722274A1 (en) 2020-10-14
PL3722274T3 (pl) 2023-12-04
DK3356313T3 (da) 2020-07-20
AU2016329261B2 (en) 2020-05-07
KR20200106097A (ko) 2020-09-10
AU2022200366A1 (en) 2022-02-17
DE202016008739U1 (de) 2019-04-29
KR102154415B1 (ko) 2020-09-10
US11154513B2 (en) 2021-10-26
EP3722274B1 (en) 2023-06-07
CN110693825A (zh) 2020-01-17
AU2020205239B9 (en) 2021-10-28
JP2018529693A (ja) 2018-10-11
CN113662928A (zh) 2021-11-19
MX2020001408A (es) 2022-04-13
CN110693825B (zh) 2022-03-08
MX2018003781A (es) 2018-09-12

Similar Documents

Publication Publication Date Title
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3072835T3 (da) Fremgangsmåde til fremføring
EP3374114A4 (en) WORKBENCH
EP3344318A4 (en) Patient interfaces
BR112016030368A2 (pt) composição oftálmica
DK3265421T3 (da) Doseringssystem
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
SI4070787T1 (sl) Farmacevtske formulacije
DK3380139T3 (da) Medikamentadministrationsanordning
DK3125898T3 (da) Farmakofor til trail-induktion
DK3199161T3 (da) Farmaceutisk præparat
DK3171701T3 (da) Infusionsanlæg
DK3348260T3 (da) Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse
EP3246047C0 (en) COMBINATION MEDICATION
EP3437644A4 (en) MEDICINE
EP3527216A4 (en) Medicine
KR20180084810A (ko) 정제 세트
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3280447T3 (da) Farmaceutiske formuleringer
DK3349827T3 (da) Lægemiddeladministrationsanordning
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
EP4233950C0 (en) NASAL ADMINISTRATION
EP3372264A4 (en) SYRINGE
EP3395344A4 (en) MEDICINE